Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent.
Leukemia blasts isolated from bone marrow aspirates of 44 adults with acute leukemia were incubated for 1 h with 0.008-32 microM bromodeoxyuridine (Brd-Urd). After dual labeling with monoclonal anti-BrdUrd antibodies and propidium iodide, the cells were analyzed by flow cytometry. Percent labeled cells and intensity of labeling were similar over concentrations of BrdUrd ranging from 0.8-32 microM--a 40-fold range. Therefore, despite potential interpatient variability in nucleoside pharmacokinetics, commonly used doses of BrdUrd which are intended to achieve steady-state plasma concentrations in the 8.0 microM range can be expected to provide a reliable estimate of the S-phase fraction.
Powell
B L
BL
Cancer Center, Wake Forest University, Winston-Salem, North Carolina 27103.
Gregory
B W
BW
Kute
T E
TE
Morgan
T M
TM
Lyerly
E S
ES
Capizzi
R L
RL
D000911:Antibodies, Monoclonal; D001973:Bromodeoxyuridine / Q000493:pharmacokinetics*; D004273:DNA, Neoplasm / Q000032:analysis*; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D004273:DNA, Neoplasm; D001973:Bromodeoxyuridine